1,3,4 Patients experience chronic and maladaptive pain that persists even with treatment
Dual-agonist robi to samo na osi GLP-1, plus dokada agonizm receptora GIP: dodatkowy insulinotropizm i modulacj metabolizmu lipidw w tkance tuszczowej
Uh, then what is the actual evidence for this concern
Wegovy (Semaglutide for Chronic Weight Management) FDA indication: Chronic weight management in adults with BMI 30 or greater, or BMI 27 or greater with at least one weight-related comorbidity Approved doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg (weekly subcutaneous injection) Target maintenance dose: 2.4 mg weekly Pediatric indication: Approved for adolescents aged 12 and older with obesity Ozempic (Semaglutide for Type 2 Diabetes) FDA indication: Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes Approved doses: 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg (weekly subcutaneous injection) Note: Not FDA-approved for weight management, though frequently prescribed off-label Rybelsus (Oral Semaglutide) FDA indication: Type 2 diabetes management Doses: 3 mg, 7 mg, 14 mg (daily oral tablet) Lower bioavailability: Oral formulation has approximately 1% bioavailability, resulting in less predictable weight loss compared to injectable forms Comprehensive semaglutide training for physicians emphasizes the importance of prescribing the correct formulation for the correct indication
